Beijing Hotgen Biotech Co Ltd. Stock Analysis 688068.SS

Beijing Hotgen Biotech Co., Ltd. engages in the development and manufacturing of in-vitro diagnostic, point-of-care-testing, and biodefense products. The company is headquartered in Beijing, Beijing and currently employs 946 full-time employees. The company went IPO on 2019-09-30. The in-vitro diagnostics business mainly engages in the development and application of in-vitro diagnostic reagents and instruments. The innovative biological drug business focuses on two core areas: antibody drugs and nucleic acid drugs. The biotechnology raw materials and AI innovative drug services business mainly includes the core technology platform of biotechnology raw materials and the biomolecular AI design platform. The firm mainly operates its businesses in the domestic and overseas markets.